Shenzhen Salubris Pharmaceuticals Co. Ltd. has disclosed new dual proprotein convertase subtilisin/kexin-type 9 (PCSK9) and lipoprotein(a) (Lp[a])-targeting agents potentially useful for the treatment of hypercholesterolemia.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized relaxin family peptide receptor 1 (RXFP1) receptor agonists reported to be potentially useful for the treatment of heart failure.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered dual antagonists of endothelin ETA receptor (EDNRA; ETRA) and angiotensin AT1 receptor (AGTR1; AT1). They are reported to be useful for the treatment of chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis and hypertension.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of arthritis and psoriasis.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has discovered new proprotein convertase subtilisin/kexin-type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase dual inhibitors. They are described as potentially useful for the treatment of hypercholesterolemia.
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead.
As China emerges as a critical commercial market and a source of global innovation, the newly released 2026 edition of Clarivate’s Drugs to Watch report highlights six drugs to watch in the China market for the year ahead.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has synthesized compounds acting as MIR124 activators reported to be useful for the treatment of inflammatory bowel disease and inflammatory disorders.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described tertiary amine compounds reported to be useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
